The Wall Street Transcript has published an in-depth interview with James Musick, President & Chief Executive Officer of Vitro Diagnostics, Inc. (OTCBB:VODG) in which he talks at length about the Company.
The entire 2,500 word interview is available free online at http://www.twst.com/ceos.htm
Vitro has developed novel technology for the generation and differentiation of adult stem cell lines. Using this technology, the Company has generated over 30 adult stem cell lines from human pancreatic tissues. Vitro also developed differentiation technology resulting in beta islets that synthesize and secrete insulin. These stem cell-derived islets may have application in drug development and discovery, diabetes research and therapy in both animals and humans.
When asked about the company’s focus, Mr. Musick stated, “We have identified a market within the pharmaceutical manufacturing sector and in biomedical research, where we will target the use of our products in acute and chronic toxicology testing together with functional tests of beta cells, allowing determination of the impact of new drug candidates on human pancreatic endocrine function. … We believe that there are limited obstacles to sharp increases in revenue and … that we can achieve a turnaround with the second year following launch.”
Regarding the marketplaces in which the company operates, Mr. Musick stated, “We have an initial (non-therapeutic) target market where pre-approval by the FDA is not necessary and we currently have available resources that are needed to manufacture and distribute our products. We have access to several human adult stem cell lines, and we’ve demonstrated the capacity of these stem cell lines for differentiation into functional beta cells.”
In closing, Mr. Musick said, “We’re in the final stages of construction of a modern extended facility that is suitable for our current manufacturing operations. … We have a seasoned management team that’s experienced in prior ventures targeting similar niche markets.”
The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673.
Vitro Diagnostics, Inc.
James R. Musick, 303-999-2130
Fax:
303-762-1240
jim@vitrodiag.com
